Iranian Journal of Pediatrics

Published by: Kowsar

Association of TNF-α Gene Variants With Clinical Manifestation of Cystic Fibrosis Patients of Iranian Azeri Turkish Ethnicity

Aziz Khorrami 1 , * , Mortaza Bonyadi 1 , Mandana Rafeey 2 and Omid Omrani 1
Authors Information
1 Faculty of Natural Science, University of Tabriz, Tabriz, IR Iran
2 Department of Pediatrics, Tabriz University of Medical Sciences, Tabriz, IR Iran
Article information
  • Iranian Journal of Pediatrics: February 28, 2015, 25 (1)
  • Published Online: February 21, 2015
  • Article Type: Research Article
  • Received: December 12, 2014
  • Accepted: December 29, 2014
  • DOI: 10.5812/ijp.307

To Cite: Khorrami A, Bonyadi M, Rafeey M, Omrani O. Association of TNF-α Gene Variants With Clinical Manifestation of Cystic Fibrosis Patients of Iranian Azeri Turkish Ethnicity, Iran J Pediatr. 2015 ;25(1):-. doi: 10.5812/ijp.307.

Abstract
Copyright: Copyright © 0, Iranian Journal of Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Dooki MR, Akhavan-Niaki H, Juibary AG. Detecting Common CFTR Mutations by Reverse Dot Blot Hybridization Method in Cystic Fibrosis First Report from Northern Iran. Iran J Pediatr. 2011; 21(1): 51-7[PubMed]
  • 2. Soleti R, Porro C, Martinez MC. Apoptotic process in cystic fibrosis cells. Apoptosis. 2013; 18(9): 1029-38[DOI][PubMed]
  • 3. Nabholz CE, von Overbeck J. Gene-environment interactions and the complexity of human genetic diseases. J Insur Med. 2004; 36(1): 47-53[PubMed]
  • 4. Bonyadi M, Omrani O, Rafeey M, Bilan N. Spectrum of CFTR gene mutations in Iranian Azeri Turkish patients with cystic fibrosis. Genet Test Mol Biomarkers. 2011; 15(1-2): 89-92[DOI][PubMed]
  • 5. Perone C, Medeiros GS, del Castillo DM, de Aguiar MJ, Januario JN. Frequency of 8 CFTR gene mutations in cystic fibrosis patients in Minas Gerais, Brazil, diagnosed by neonatal screening. Braz J Med Biol Res. 2010; 43(2): 134-8[PubMed]
  • 6. Farjadian S, Moghtaderi M, Kashef S, Alyasin S, Najib K, Saki F. Clinical and genetic features in patients with cystic fibrosis in southwestern iran. Iran J Pediatr. 2013; 23(2): 212-5[PubMed]
  • 7. Antunovic SS, Lukac M, Vujovic D. Longitudinal cystic fibrosis care. Clin Pharmacol Ther. 2012; 93(1): 86-97
  • 8. Collaco JM, Cutting GR. Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med. 2008; 14(6): 559-66[DOI][PubMed]
  • 9. Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet. 2005; 6: 237-60
  • 10. Buscher R, Grasemann H. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road? Naunyn Schmiedebergs Arch Pharmacol. 2006; 374(2): 65-77[DOI][PubMed]
  • 11. Slavotinek A, Biesecker LG. Genetic modifiers in human development and malformation syndromes, including chaperone proteins. Hum Mol Genet. 2003; 12 Spec No 1-50[PubMed]
  • 12. Feng RN, Zhao C, Sun CH, Li Y. Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS One. 2011; 6(4)[DOI][PubMed]
  • 13. Nieves-Ramirez ME, Partida-Rodriguez O, Alegre-Crespo PE, Tapia-Lugo Mdel C, Perez-Rodriguez ME. Characterization of Single-Nucleotide Polymorphisms in the Tumor Necrosis Factor alpha Promoter Region and in Lymphotoxin alpha in Squamous Intraepithelial Lesions, Precursors of Cervical Cancer. Transl Oncol. 2011; 4(6): 336-44[PubMed]
  • 14. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997; 94(7): 3195-9[PubMed]
  • 15. van Heel DA, Udalova IA, De Silva AP, McGovern DP, Kinouchi Y, Hull J, Lench NJ, Cardon LR, Carey AH, Jewell DP, Kwiatkowski D, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet. 2002; 11(11): 1281-9[PubMed]
  • 16. Zuniga J, Vargas-Alarcon G, Hernandez-Pacheco G, Portal-Celhay C, Yamamoto-Furusho JK, Granados J. Tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with systemic lupus erythematosus (SLE). Genes Immun. 2001; 2(7): 363-6[DOI][PubMed]
  • 17. Fernandez-Celemin L, Pasko N, Blomart V, Thissen JP. Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab. 2002; 283(6)-90[DOI][PubMed]
  • 18. Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res. 2001; 2(5): 269-72[PubMed]
  • 19. Grounds MD. Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology. 2002; 3(1-2): 19-24[PubMed]
  • 20. Shmarina G, Pukhalsky A, Petrova N, Zakharova E, Avakian L, Kapranov N, Alioshkin V, et al. TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression. J Transl Med. 2013; 11: 19[DOI][PubMed]
  • 21. Mishra A, Greaves R, Massie J. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era. Clin Biochem Rev. 2005; 26(4): 135-53[PubMed]
  • 22. Bonyadi M, Jahanafrooz Z, Esmaeili M, Kolahi S, Khabazi A, Ebrahimi AA, Hajialilo M, Dastgiri S, et al. TNF-alpha gene polymorphisms in Iranian Azeri Turkish patients with Behcet's Disease. Rheumatol Int. 2009; 30(2): 285-9[DOI][PubMed]
  • 23. Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med. 2002; 347(6): 401-7[DOI][PubMed]
  • 24. Hardin DS. GH improves growth and clinical status in children with cystic fibrosis -- a review of published studies. Eur J Endocrinol. 2004; 151 Suppl 1-5[PubMed]
  • 25. Shmarina GV, Pukhalsky AL, Kokarovtseva SN, Pukhalskaya DA, Shabalova LA, Kapranov NI, Kashirskaja NJ, et al. Tumor necrosis factor-alpha/interleukin-10 balance in normal and cystic fibrosis children. Mediators Inflamm. 2001; 10(4): 191-7[DOI][PubMed]
  • 26. Baudouin-Legros M, Hinzpeter A, Jaulmes A, Brouillard F, Costes B, Fanen P, Edelman A, et al. Cell-specific posttranscriptional regulation of CFTR gene expression via influence of MAPK cascades on 3'UTR part of transcripts. Am J Physiol Cell Physiol. 2005; 289(5)-50[DOI][PubMed]
  • 27. Ramachandran S, Karp PH, Osterhaus SR, Jiang P, Wohlford-Lenane C, Lennox KA, Jacobi AM, Praekh K, Rose SD, Behlke MA, Xing Y, Welsh MJ, McCray PJ, et al. Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs. Am J Respir Cell Mol Biol. 2013; 49(4): 544-51[DOI][PubMed]
  • 28. Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax. 1998; 53(12): 1018-21[PubMed]
  • 29. Yarden J, Radojkovic D, De Boeck K, Macek MJ, Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H, et al. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax. 2005; 60(4): 320-5[DOI][PubMed]
  • 30. Joos L, Pare PD, Sandford AJ. Genetic risk factors of chronic obstructive pulmonary disease. Swiss Med Wkly. 2002; 132(3-4): 27-37[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader